NovoCure Ltd — Director's Dealing 2018

Jun 5, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2018-05-31

Reporting Person: Madden Martin J. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-31	Options to Buy Ordinary Shares	$31.45	A	17891	Acquired	2028-05-31	Ordinary Shares (17891)	Direct
2018-05-31	Restricted Stock Unit	$	A	8906	Acquired		Ordinary Shares (8906)	Direct

Footnotes

F1: Options to buy 17,891 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders.

F2: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share.

F3: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders.